PTGER3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL585953	1.00	15/20
SCHEMBL157606	0.73	13/20
Beraprost (SCHEMBL34593)	0.53	13/20
Enprostil (SCHEMBL186877)	0.64	12/20
SCHEMBL309761	0.63	12/20
Fenprostalene (SCHEMBL564040)	0.63	11/20
SCHEMBL265281	0.50	10/20
SCHEMBL242586	0.51	8/20
SCHEMBL71453	0.68	7/20
Etiproston (SCHEMBL571117)	0.67	7/20
SCHEMBL78555	0.55	7/20
SCHEMBL78556	0.55	7/20
Nocloprost (SCHEMBL436204)	0.84	6/20
Sulprostone (SCHEMBL94842)	0.77	6/20
Sulprostone (SCHEMBL94843)	0.77	6/20
SCHEMBL344775	0.70	6/20
SCHEMBL344776	0.70	6/20
SCHEMBL344657	0.68	6/20
SCHEMBL344658	0.68	6/20
SCHEMBL94570	0.66	6/20

Clinical trials — most relevant to PTGER3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis	PHASE4	COMPLETED
Type 2 Diabetes Mellitus and Atherosclerosis	PHASE4	UNKNOWN
Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients	PHASE4	COMPLETED
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA	PHASE2/PHASE3	COMPLETED
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids	PHASE2/PHASE3	COMPLETED
Go Fish: Omega-3 Fatty Acid Supplementation in Diabetes-Related Kidney Disease	PHASE3	COMPLETED
Montelukast for Early Life Wheezing	PHASE2/PHASE3	COMPLETED
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT	PHASE2	NOT_YET_RECRUITING
The Effects of Omega-3 Fatty Acids on Aspirin Resistance	PHASE1/PHASE2	COMPLETED
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine	PHASE2	WITHDRAWN
HTL0039732 in Participants With Advanced Solid Tumours	PHASE1/PHASE2	RECRUITING
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction	PHASE2	COMPLETED
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors	PHASE1	COMPLETED
The Effect of Resolvins on the Resolve of Inflammatory Low Back Pain	nan	UNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Prebiotics and Diet to Reduce Leaky Gut in First Degree Relatives of Crohn's Disease Patients	nan	COMPLETED
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation	nan	COMPLETED
Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)	nan	NOT_YET_RECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis	nan	COMPLETED
Adjunct Use of Diode Laser Therapy and Omega 3 Gel in Local Drug Delivery Approach on The Treatment of Localized Aggressive Periodontitis	nan	COMPLETED
Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)	nan	COMPLETED
The Effects of Lipinova on Inflammatory and Proresolving Lipid Mediator Profiles After Orthopedic Surgery	nan	UNKNOWN
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTGER3 binder may also engage these)

Protein	Name	Similarity
P46069	—	1.000	P46069 →
P50131	—	0.997	P50131 →
P30557	—	0.996	P30557 →
P34979	—	0.996	P34979 →
P34980	—	0.995	P34980 →
Q62053	—	0.988	Q62053 →
P43117	—	0.984	P43117 →
Q62928	—	0.984	Q62928 →
PTGER2	Prostaglandin E2 receptor EP2 subtype	0.984	landscape →
P43118	—	0.981	P43118 →
Q9XT82	—	0.980	Q9XT82 →
Q9R261	—	0.979	Q9R261 →
P43253	—	0.978	P43253 →
P30987	—	0.977	P30987 →
P70263	—	0.977	P70263 →
Q95KZ0	—	0.977	Q95KZ0 →
Q95125	—	0.977	Q95125 →
PTGER4	Prostaglandin E2 receptor EP4 subtype	0.976	landscape →
P43252	—	0.975	P43252 →
P47752	—	0.975	P47752 →
O35932	—	0.975	O35932 →
P37289	—	0.974	P37289 →
Q28905	—	0.974	Q28905 →
P32240	—	0.974	P32240 →
Q8MJ08	—	0.974	Q8MJ08 →
Q28691	—	0.972	Q28691 →
PTGFR	Prostaglandin F2-alpha receptor	0.972	landscape →
P34978	—	0.972	P34978 →
P52592	—	0.971	P52592 →
P43114	—	0.970	P43114 →